Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Epilepsy (Jan 2020)

Posted by Matt Breese on Jan 24, 2020

Find me on:

According to our recent payer coverage analysis for epilepsy treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for epilepsy treatments shows that under the pharmacy benefit, almost 31% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Epilepsy-1Q2020Data snapshot as of Q1 2020

Trends: In January 2020, the FDA approved Neurelis, Inc.'s Valtoco (diazepam nasal spray) as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are different from usual seizure patterns in people at least 6 years old with epilepsy.  

To read the full Reality Check on Epilepsy treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing